atai Life Sciences (NASDAQ:ATAI, ETR:9VC) chief scientific officer Glenn Short spoke with Proactive about the company’s recent NIH grant and its innovative discovery program targeting opioid use disorder (OUD).  Short explained that the NIH grant review process is “highly competitive,” with independent experts assessing the novelty and potential impact of atai’s work.   He said this was the first time external reviewers had a chance to examine the company’s serotonergic 2A/2C agonists, compounds with non-ha ...